RxDoctor Payments Data

Sundeep Deorah, MD

Urology · Richmond, VANPI 1558572842

Payments from drug & device makers

$1,852in general payments, 2019–2025

Across 81 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$350
  • Astellas Pharma US Inc$263
  • AbbVie$220
  • Dornier Medtech America, Inc$180
  • Blue Earth Diagnostics$96
  • Johnson & Johnson$93
  • plus $650 from 18 others

What the payments were for

  • Food & beverage$1,84099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,852 in reported general payments places this provider in the 40th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$307,294
Medicare patients
704
Services billed
14,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide23$337,244
Abiraterone Acetate23$96,087
Tamsulosin Hcl711$8,796
GemtesaVibegron15$8,655
Finasteride226$3,381
Potassium Citrate ErPotassium Citrate14$1,797
Silodosin20$1,683
Tadalafil20$1,313
Oxybutynin Chloride ErOxybutynin Chloride37$1,091
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$754
Alfuzosin Hcl ErAlfuzosin Hcl31$658
Cephalexin93$642
Testosterone Cypionate14$587
Ketorolac Tromethamine20$260
Ciprofloxacin Hcl66$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$38$337,24423 claims
Sumitomo Pharma America, Inc.Gemtesa$78$8,65515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →